dibutylnitrosamine (N-nitrosodi-n-butylamine)

07/01/1987 - "Activation of N-ras gene in a rat hepatocellular carcinoma induced by dibutylnitrosamine and butylated hydroxytoluene."
12/01/2009 - "The human hepatoma cell line (HepG2) exhibited a dose and time-dependent apoptotic response following treatment with N-Nitrosopiperidine (NPIP) and N-Nitrosodibutylamine (NDBA), two recognized human carcinogens. "
07/01/1987 - "DNA samples from eighteen rat hepatocellular carcinomas, including those induced by oral administration of dibutylnitrosamine (DBN) with butylated hydroxytoluene (BHT), or DBN with butylated hydroxyanisole (BHA), have been tested for the presence of transforming activity by transfection assay with NIH3T3 cells. "
10/01/2009 - "The aim of this study was to investigate the protective effect of myricetin, quercetin, (+)-catechin and (-)-epicatechin, against N-nitrosodibutylamine (NDBA) and N-nitrosopiperidine (NPIP)-induced DNA damage in human hepatoma cells (HepG2). "
07/01/2009 - "The aim of this work was to determine the effect of vitamin C, diallyl disulfide (DADS) and dipropyl disulfide (DPDS) towards N-nitrosopiperidine (NPIP) and N-nitrosodibutylamine (NDBA)-induced apoptosis in human leukemia (HL-60) and hepatoma (HepG2) cell lines using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay. "

01/01/1991 - "In our animal experiments we used a chemical agent (dibutylnitrosamine) to induce urinary bladder tumor in rats, then this was implanted under the dorsal skin of rats of the same strain to gain a standard tumor preparation. "
03/01/1987 - "Induction of tumors in the liver, urinary bladder, esophagus and forestomach by short-term treatment with different doses of N,N'-dibutylnitrosamine in rats."
05/01/1977 - "Ultrastructure of N-dibutylnitrosamine-induced tumors of the urinary bladder in European hamsters."
11/01/1989 - "[Induction of urinary bladder urothelial cancers in the rabbit by dibutylnitrosamine with an artificial bladder calculus as cocarcinogen]."
03/01/1985 - "Of the three metabolic oxidation pathways of N-nitrosodibutylamine (NDBA) demonstrated in vivo, omega oxidation is responsible for the induction of bladder tumors, while omega-1 and omega-2 oxidations are considered to be associated with the induction of liver tumors by NDBA. "

05/08/2003 - "High susceptibility of p53 knockout mice to esophageal and urinary bladder carcinogenesis induced by N, N-dibutylnitrosamine."
01/01/1971 - "Dibutylnitrosamine carcinogenesis in Syrian Golden and Chinese hamsters."
01/01/1990 - "[Proliferation kinetics in rat urothelium after unilateral nephrectomy and various doses of dibutylnitrosamine application--an example of the roles of a one kidney state on carcinogenesis]."
12/15/1988 - "The modifying effects of concomitant antioxidant treatment on N,N-dibutylnitrosamine (DBN)-induced carcinogenesis were investigated. "
04/15/1987 - "The modifying effects of antioxidants were examined in a carcinogenesis system after N,N-dibutylnitrosamine treatment. "

11/01/1985 - "8. N-Nitrosodibutylamine and omega-fluorinated analogues: in vivo metabolism in relation to the induction of urinary bladder cancer in the rat."
03/01/1979 - "Of 4 samples from bladder cancer patients, 2 contained nitrosodibutylamine (0.35 and 0.66). "
12/01/1973 - "Establishment and characterization of a transplantable dibutylnitrosamine-induced mouse bladder tumor line FCB."
03/01/1985 - "Of the three metabolic oxidation pathways of N-nitrosodibutylamine (NDBA) demonstrated in vivo, omega oxidation is responsible for the induction of bladder tumors, while omega-1 and omega-2 oxidations are considered to be associated with the induction of liver tumors by NDBA. "
01/01/1975 - "Cystoscopy of chemically induced bladder neoplasms in rabbits administered the carcinogen dibutylnitrosamine."

01/01/1988 - "Administration of 46.5 mg/kg N-nitrosodibutylamine (NBN), which is a carcinogen but not a GT activator, did not affect GT activities or liver body weights."
09/10/1996 - "Single-dose treatment (20 mg/kg body weight) of male mice with ethylbutylnitrosamine, propylbutylnitrosamine, or dibutylnitrosamine: increased (1) the activity of DMN-dI by 108%, 104%, 51%, respectively; (2) the cytochrome P-450 content by 106%, 72%, 51%, respectively; (3) the activity of AHH by 95%, 106%, 80% respectively; (4) the cytochrome b5 content by 164%, 97%, 94% respectively; and (5) decreased the activity of NADPH-cytochrome c reductase by 55%, 50% and 45%, respectively. "
01/01/1988 - "C57W and SHR mice were given intraperitoneal injections of 100 or 300 mg/kg body weight glucuronic acid (in isotonic NaCl solution) 15-30 minutes prior to treatment with urethan, dibutylnitrosamine or 7,12-dimethyl-1,2-benzanthracene. "
01/01/2014 - "In addition, biomarkers of cardiovascular diseases such as creatine kinase MB activity (CK-MB) and lactate dehydrogenase (LDH) as well as protein expression of both glutathione peroxidase and glutathione S-transferase π isozyme were assayed after treatment of rats with 0.2 mg/kg body weight of N-nitrosodibutylamine (NDBA), N-nitrosoethylbutylamine (NEBA), N-nitrosobutylpropylamine (NBPA), N-nitrosodiethylamine (NDEA), N-nitrosodimethylamine (NDMA), and N-nitrosodiphenylamine (NDPA) as a daily dose for two weeks. "